|
|
Article: Study designed to discover the genomic marker for patients at risk of clozapine-induced agranulocytosis.
- Article from:
- Genomics & Genetics Weekly
- Article date:
- May 24, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 MAY 24 - (NewsRx.com & NewsRx.net) -- Genaissance Pharmaceuticals, Inc., (GNSC), announced that the first patient was enrolled in its clinical study designed to discover the genomic marker(s) for identifying patients at risk of clozapine-induced agranulocytosis, a potentially life-threatening depletion of white blood cells.
The CARING (Clozapine and Agranulocytosis Relationships Investigated by Genetics (HAP Markers)) Study is the first study in the company's HAP-Clozapine development plan, and is designed to provide the information that may ultimately enable physicians to prescribe HAP-Clozapine to patients while minimizing or eliminating the need for the ...